TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mayne Pharma Group ( (AU:MYX) ) has issued an announcement.
Mayne Pharma Group Limited announced an update regarding its proposed acquisition by Cosette Pharmaceuticals, with the Foreign Investment Review Board extending the statutory deadline for approval to 17 November 2025. The acquisition scheme remains contingent on FIRB and court approvals, among other conditions, but the indicative timetable remains unchanged. Shareholders are advised that no action is required from them at this time.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide better, safer, and more accessible medicines. It is a leader in dermatology and women’s health in the United States and offers contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has successfully developed and commercialized new oral drug delivery systems.
Average Trading Volume: 447,256
Technical Sentiment Signal: Sell
Current Market Cap: A$374.5M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.